Prediction of delayed treatment response in pulmonary tuberculosis: Use of time to positivity values of Bactec cultures

Tuberculosis

Volumn 88, Issue 6, 2008, Pages 624-630

  Carroll, N M ^a,b   Uys, P ^a,b   Hesseling, A ^b   Lawrence, K ^b   Pheiffer, C ^a,b   Salker, F ^b   Duncan, K ^c   Beyers, N ^b   van Helden, P D ^a,b  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bactec; Response; Time to positivity; Treatment; Tuberculosis

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SPUTUM ANALYSIS; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; BIOMARKERS, PHARMACOLOGICAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 54349117757     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2008.03.003     Document Type: Article

References (21)

1. Duncan K. Progress in TB drug development and what is still needed. Tuberculosis 83 (2003) 201-207
2. Baumann S., Nasser Eddine A., and Kaufmann S.H. Progress in tuberculosis vaccine development. Curr Opin Immunol 18 (2006) 438-448
3. Keane V.P., De Klerk N., Krieng T., Hammond G., and Musk A.W. Risk factors for the development of non-response to first line treatment for tuberculosis in southern Vietnam. Int J Epidemiol 26 (1997) 1115-1120
4. Enarson D.E., Rieder H.L., Arnadottir T., and Trebucq A. Management of tuberculosis: a guide for low income countries. [pamphlet]. France: Fifth IUATLD (2000)
5. Chavez Pachez A.M., Blank R., Smith Fawzi M.C., Bayona J., Becerra M.C., and Mitnick C.D. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 8 (2004) 52-58
6. Santha T., Garg R., Frieden T.R., Chandrasekaran V., Subramani R., Gopi P.G., et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India. Int J Tuberc Lung Dis 2002 6 (2000) 780-788
7. Rieder H.L. Sputum smear conversion during directly observed treatment for tuberculosis. Tuberc Lung Dis 77 (1996) 124-129
8. Epstein M.D., Schluger N.W., Davidow A.L., Bonk S., Rom W.N., and Hanna B. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 113 (1998) 379-386
9. Chierakul N., Chaiprasert A., Tingtoy N., Arjratanakul W., and Pattanakitsakul S.N. Can serial qualitative polymerase chain reaction monitoring predict outcome of pulmonary tuberculosis treatment?. Respirology 6 (2001) 305-309
10. Levee G., Glaziou P., Gicquel B., and Chanteau S. Follow-up of tuberculosis patients undergoing standard anti-tuberculosis chemotherapy by using a polymerase chain reaction. Res Microbiol 145 (1994) 5-8
11. Afghani B., Lieberman J.M., Duke M.B., and Stutman H.R. Comparison of quantitative polymerase chain reaction, acid fast bacilli smear, and culture results in patients receiving therapy for pulmonary tuberculosis. Diag Microbiol Infect Dis 29 (1997) 73-79
12. Desjardin L.E., Perkins M.D., Wolski K., Haun S., Teixeira L., Chen Y., et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 160 (1999) 203-210
13. Wallis R.S., Perkins M.D., Phillips M., Joloba M., Namale A., Johnson J.L., et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 161 (2000) 1076-1080
14. Brahmbhatt S., Black G.F., Carroll N.M., Beyers N., Salker F., Kidd M., et al. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol 146 (2006) 243-252
15. Carroll N.M., Richardson M., Engelke E., de Kock M., Lombard C., and van Helden P.D. Reduction of the rate of false-positive cultures of Mycobacterium tuberculosis in a laboratory with a high culture positivity rate. Clin Chem Lab Med 40 (2002) 888-892
16. BACTEC 460TB Systems product and procedure manual (1996), Becton-Dickinson Diagnostic Instrument Systems, Sparks, MD
17. Ramarokoto H., Randriamiharisoa H., Rakotoarisaonina A., Rasolovavalona T., Rasolofo V., Chanteau S., et al. Bacteriological follow-up of tuberculosis treatment: a comparative study of smear microscopy and culture results at the second month of treatment. Int J Tuberc Lung Dis 6 (2002) 909-912
18. Zhao F.Z., Levy M.H., and Wen S. Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis 1 (1997) 570-572
19. Jindani A., Dore C.J., and Mitchison D.A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167 (2003) 1348-1354
20. The Provincial Administration of The Western Cape Metropole Region and City Health. City of Cape Town/Metropole Region TB Control Programme Progress Report 1997-2002. Available at:. http://www.capegateway.gov.za/Text/2003/12/cct_tb_report_1997to2002.pdf
21. Aber V.R., and Nunn A.J. Short term chemotherapy of tuberculosis: factors affecting relapse following short term chemotherapy. Bull Int Union Tuberc 53 (1978) 276-280